Who founded Volitionrx?

Volitionrx was founded by Jacob Micallef, Jake Micallef, Mark Eccleston.

How much funding has Volitionrx raised?

Volitionrx has disclosed $52.6M raised across 8 rounds.

Where is Volitionrx headquartered?

Volitionrx is headquartered in Henderson, US.

Volitionrx

NYSE: VNRX

Henderson, US · Delaware corporation

Find your way into Volitionrx

643 people in our graph can introduce you to the Volitionrx team.

Paths you didn't know you had: your email and LinkedIn already hold routes to the Volitionrx team. We find them
2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Volition develops Nu.Q epigenetics-based blood tests that detect nucleosome changes associated with cancer, sepsis, and other diseases in both humans and animals. Its products include diagnostic assays for NETosis detection, research-use assays, and a canine cancer blood test.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Jacob MicallefChief Scientific Officer

Jake MicallefChief Scientific Officer

Mark Eccleston Co-founding ScientistMark Eccleston is a co-founding scientist at VolitionRx who has spent over 13 years developing the company's epigenetics-based blood test technology, serving previously as Chief Technology Officer and Business Development Director, and holds 25 patents related to the platform. He has a background in organic and polymer chemistry with expertise in biodegradable polymers for drug delivery, and through his consultancy OncoLytika has provided scientific and management support to VolitionRx's diagnostic and therapeutic development programs.

Terig Hughes Chief Financial OfficerTerig Hughes has over 20 years of international experience in finance and business leadership across healthcare, scientific publishing, digital health, and biotechnology sectors in Europe, North America, and Asia Pacific. He joined Volitionrx as Group Chief Financial Officer and has held senior finance roles in London, Amsterdam, Philadelphia, and Singapore, with expertise in P&L management, financial planning, and leading cross-functional teams.

Salvatore Thomas ButeraExecutive

Rodney RootsaertExecutive

Louise Batchelor Group Chief Marketing & Communications OfficerLouise Batchelor is Group Chief Marketing & Communications Officer at Volition, which develops blood tests detecting disease-associated nucleosome changes in humans and animals. She brings over 25 years of marketing and sales experience across FMCG, healthcare, retail, and strategic consulting, including executive roles at a publicly-listed company.

Gael ForterreChief Commercial Officer (CCO)

Gaetan MichelChief Operating Officer

Jasmine KwayChief Revenue Officer

David Cecil VanstonChief Financial Officer

Jason Terrell Chief Executive Officer of Volition AmericaJason Terrell is Chief Medical Officer at Volition, which develops blood tests based on epigenetic markers for cancer and other disease detection. He previously founded and scaled clinical laboratory businesses and held senior leadership roles in early-stage diagnostic and therapeutic development companies.

Reported raises · per SEC filings

Form D private placements

$52.6M disclosed across 8 rounds · 2014–2025

▶$22.6MraisedJan 2026 · 1 investors · Biotechnology

Rule 506(b)